TC BioPharm (Holdings) plc (TCB) is a clinical-stage biopharmaceutical company with a cell-based product pipeline capable of treating a variety of disorders including cancer and infectious disease.
Company profile
Ticker
TCBP, TCBPW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TC BioPharm (Holdings) Ltd
SEC CIK
TCBP stock data
Latest filings (excl ownership)
8-K
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
4 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
19 Mar 24
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Unregistered Sales of Equity Securities
12 Mar 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
DEF 14A
Definitive proxy
20 Feb 24
8-K
TCBP Provides Shareholder Update and Highlights Upcoming Milestones
14 Feb 24
PRE 14A
Preliminary proxy
9 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Jan 24
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
MEDINET Co., Ltd.
29 Jan 24
SC 13G
Nipro Corp
28 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
MEDINET Co., Ltd.
30 Jan 23
4
Diana Elizabeth Randall
11 Jan 23
4/A
Mark Edward Randall
11 Jan 23
4/A
Kenneth Edward Randall
11 Jan 23
4
Mark Edward Randall
11 Jan 23
4
Kenneth Edward Randall
11 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 8 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 648.10 mm |
Total shares | 3.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Alta Partners | 2.93 mm | $6.20 mm |
Renaissance Capital Partners | 382.96 k | $1.80 mm |
Armistice Capital | 297.50 k | $127.93 mm |
MEDINET | 73.50 k | $0.00 |
Csenge Advisory | 26.00 k | $11.18 mm |
Cresset Asset Management | 25.00 k | $10.75 mm |
Modera Wealth Management | 16.24 k | $466.03 mm |
XTX Topco | 13.62 k | $5.69 mm |
Citadel Advisors | 13.54 k | $5.65 mm |
Two Sigma Securities | 13.40 k | $5.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Nov 22 | Renaissance Capital Partners | Ordinary Shares [ADS] | Buy | Acquire P | No | No | 5 | 70,000 | 350.00 k | 136,834 |
30 Nov 22 | Renaissance Capital Partners | Series B Warrants Ordinary Shares | Buy | Acquire P | No | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Renaissance Capital Partners | Series A Warrants Ordinary Shares | Buy | Acquire P | No | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Kenneth Edward Randall | Ordinary Shares [ADS] | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 382,963 |
30 Nov 22 | Kenneth Edward Randall | Series B Warrants Ordinary Shares | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Kenneth Edward Randall | Series A Warrants Ordinary Shares | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Mark Edward Randall | Ordinary Shares [ADS] | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 382,963 |
30 Nov 22 | Mark Edward Randall | Series B Warrants Ordinary Shares | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Mark Edward Randall | Series A Warrants Ordinary Shares | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 70,000 |
30 Nov 22 | Kenneth Edward Randall | Ordinary Shares [ADS] | Buy | Acquire P | Yes | No | 5 | 70,000 | 350.00 k | 136,834 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
8 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
5 Apr 24
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
4 Apr 24
Press releases
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
4 Apr 24
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
2 Apr 24
TCBP Adjourns General Meeting Until a Later Date
19 Mar 24
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
13 Mar 24
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"
1 Mar 24